Sign in

    Clement Sears • Stifel Financial Corp.

    Clement Sears is an analyst at Stifel Financial Corp., specializing in equity research, though specific details about his full job title, sector specialization, and the companies he covers are not available in public records. There is no verifiable information regarding his performance metrics, ranking, or investment track record, nor are there confirmed details about previous roles or a career timeline. Likewise, professional credentials, such as FINRA licenses or industry awards, could not be located for Clement Sears. Without a LinkedIn profile or official corporate biography, more granular information about his achievements or responsibilities remains unavailable.

    Clement Sears's questions to Nanobiotix SA (NBTX) leadership

    Clement Sears's questions to Nanobiotix SA (NBTX) leadership • FY 2023

    Question

    Clement Sears of Stifel asked for an update on Nanobiotix's other technology platforms like Curadigm, including their development stage, the status of the Sanofi collaboration, and whether these platforms have been discussed with Johnson & Johnson.

    Answer

    CEO Laurent Levy detailed the company's other platforms, including a CNS-focused platform and the Curadigm (Nanoprimer) platform designed to alter drug biodistribution. He noted that Curadigm has multiple proof-of-concepts and an update on its business model is expected by year-end. The Sanofi collaboration yielded good data, with next steps being considered within the platform's broader strategy. He confirmed that these other platforms have not been discussed with J&J, as the current focus remains entirely on NBTXR3.

    Ask Fintool Equity Research AI